Molecular Imaging and Biology

, Volume 19, Issue 2, pp 271–279 | Cite as

Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts

  • Alexandr Kristian
  • Jon Erik Holtedahl
  • Turid Torheim
  • Cecilia Futsaether
  • Eivor Hernes
  • Olav Engebraaten
  • Gunhild M. Mælandsmo
  • Eirik Malinen
Research Article

Abstract

Purpose

Non-invasive response monitoring can potentially be used to guide therapy selection for breast cancer patients. We employed dynamic 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography ([18F]FDG PET) to evaluate changes in three breast cancer xenograft lines in mice following three chemotherapy regimens.

Procedures

Sixty-six athymic nude mice bearing bilateral breast cancer xenografts (two basal-like and one luminal-like subtype) underwent three 60 min [18F]FDG PET scans. Scans were performed prior to and 3 and 10 days after treatment with doxorubicin, paclitaxel, or carboplatin. Tumor growth was monitored in parallel. A pharmacokinetic compartmental model was fitted to the tumor uptake curves, providing estimates of transfer rates between the vascular, non-metabolized, and metabolized compartments. Early and late standardized uptake values (SUVE and SUVL, respectively); the rate constants k1, k2, and k3, and the intravascular fraction vB were estimated. Changes in tumor volume were used as a response measure. Multivariate partial least-squares regression (PLSR) was used to assess if PET parameters could model tumor response and to identify PET parameters with the largest impact on response.

Results

Treatment responders had significantly larger perfusion-related parameters (k1 and k2) and lower metabolism-related parameter (k3) than non-responders 10 days after the start of treatment. These findings were further supported by the PLSR analysis, which showed that k1 and k2 at day 10 and changes in k3 explained most of the variability in response to therapy, whereas SUVL and particularly SUVE were of lesser importance.

Conclusions

Overall, rate parameters related to both tumor perfusion and metabolism were associated with tumor response. Conventional metrics of [18F]FDG uptake such as SUVE and SUVL apparently had little relation to tumor response, thus necessitating full dynamic scanning and pharmacokinetic analysis for optimal evaluation of chemotherapy-induced changes in breast cancers.

Key words

Positron emission tomography Breast cancer Chemotherapy 2-deoxy-2-[18F]fluoro-D-glucose Pharmacokinetic analysis Partial least-squares regression 

References

  1. 1.
    Weigel MT, Dowsett M (2010) Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 17:R245–R262CrossRefPubMedGoogle Scholar
  2. 2.
    Perou CM, Sorlie T, Eisen MB, et al. (2000) Molecular portraits of human breast tumours. Nature 406:747–752CrossRefPubMedGoogle Scholar
  3. 3.
    Sørlie T, Perou CM, Tibshirani R, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98:10869–10874CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Sørlie T, Tibshirani R, Parker J, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418–8423CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Tannock I (2001) Tumor physiology and drug resistance. Cancer Metastasis Rev 20:123–132CrossRefPubMedGoogle Scholar
  6. 6.
    An YY, Kim SH, Kang BJ, Lee AW (2015) Treatment response evaluation of breast cancer after neoadjuvant chemotherapy and usefulness of the imaging parameters of MRI and PET/CT. J Korean Med Sci 30:808–815CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kubota K (2001) From tumor biology to clinical pet: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 15:471–486CrossRefPubMedGoogle Scholar
  8. 8.
    El Naqa I, Grigsby P, Apte A, et al. (2009) Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recogn 42:1162–1171CrossRefGoogle Scholar
  9. 9.
    Yoshioka T, Takahashi H, Oikawa H, et al. (1997) Influence of chemotherapy on FDG uptake by human cancer xenografts in nude mice. J Nucl Med 38:714–717PubMedGoogle Scholar
  10. 10.
    Humbert O, Berriolo-Riedinger A, Cochet A, et al. (2014) Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer. Eur J Nucl Med Mol Imaging 41:416–427CrossRefPubMedGoogle Scholar
  11. 11.
    Watabe H, Ikoma Y, Kimura Y, Naganawa M, Shidahara M (2006) PET kinetic analysis—compartmental model. Ann Nucl Med 20:583–588CrossRefPubMedGoogle Scholar
  12. 12.
    Dunnwald LK, Doot RK, Specht JM, et al. (2011) PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clin Cancer Res 17:2400–2409CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Humbert O, Cochet A, Coudert B, et al. (2015) Role of positron emission tomography for the monitoring of response to therapy in breast cancer. Oncologist 20:94–104CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kasamon YL, Jones RJ, Wahl RL (2007) Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 48(Suppl 1):19s–27sPubMedGoogle Scholar
  15. 15.
    Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122s–150sCrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lind P, Igerc I, Beyer T, Reinprecht P, Hausegger K (2004) Advantages and limitations of FDG PET in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging 31(Suppl 1):S125–S134PubMedGoogle Scholar
  17. 17.
    Lim I, Noh WC, Park J, et al. (2014) The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 41:1852–1860CrossRefPubMedGoogle Scholar
  18. 18.
    Semple SI, Staff RT, Heys SD, et al. (2006) Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration. Ann Oncol 17:1393–1398CrossRefPubMedGoogle Scholar
  19. 19.
    Malinen E, Rodal J, Knudtsen IS, Sovik A, Skogmo HK (2011) Spatiotemporal analysis of tumor uptake patterns in dynamic (18)FDG-PET and dynamic contrast enhanced CT. Acta Oncol 50:873–882CrossRefPubMedGoogle Scholar
  20. 20.
    Mullani NA, Herbst RS, O'Neil RG, Gould KL, Barron BJ, Abbruzzese JL (2008) Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow. J Nucl Med 49:517–523CrossRefPubMedGoogle Scholar
  21. 21.
    Kristian A, Revheim ME, Qu H, et al. (2013) Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts. Acta Oncol 52:1566–1572CrossRefPubMedGoogle Scholar
  22. 22.
    Bergamaschi A, Hjortland GO, Triulzi T, et al. (2009) Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol 3:469–482CrossRefPubMedGoogle Scholar
  23. 23.
    Marangoni E, Vincent-Salomon A, Auger N, et al. (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13:3989–3998CrossRefPubMedGoogle Scholar
  24. 24.
    Roe K, Aleksandersen TB, Kristian A, et al. (2010) Preclinical dynamic 18F-FDG PET—tumor characterization and radiotherapy response assessment by kinetic compartment analysis. Acta Oncol 49:914–921CrossRefPubMedGoogle Scholar
  25. 25.
    Wold S, Sjöström M, Eriksson L (2001) PLS-regression: a basic tool of chemometrics. Chemom Intell Lab Syst 58:109–130CrossRefGoogle Scholar
  26. 26.
    Esbensen KH, Guyot D, Westad F, Houmøller LP, Camo ASA (2001) Multivariate Calibration (PCR/PLSR). In Multivariate data analysis—in practice: an introduction to multivariate data analysis and experimental design. Oslo: Camo, pp 115–170Google Scholar
  27. 27.
    Specht JM, Kurland BF, Montgomery SK, et al. (2010) Tumor metabolism and blood flow as assessed by PET varies by tumor subtype in locally advanced breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 16:2803–2810CrossRefGoogle Scholar
  28. 28.
    Dunnwald LK, Gralow JR, Ellis GK, et al. (2008) Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 26:4449–4457CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Cochet A, Pigeonnat S, Khoury B, et al. (2012) Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors. J Nucl Med 53:512–520CrossRefPubMedGoogle Scholar
  30. 30.
    Kristian A, Nilsen LB, Roe K, et al. (2013) Dynamic (18) F-FDG PET for assessment of tumor physiology in two breast carcinoma xenografts. Nucl Med Mol Imaging 47:173–180CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© World Molecular Imaging Society 2016

Authors and Affiliations

  • Alexandr Kristian
    • 1
    • 2
    • 3
  • Jon Erik Holtedahl
    • 4
  • Turid Torheim
    • 5
  • Cecilia Futsaether
    • 5
  • Eivor Hernes
    • 6
  • Olav Engebraaten
    • 1
    • 2
    • 3
    • 7
  • Gunhild M. Mælandsmo
    • 1
    • 2
    • 8
  • Eirik Malinen
    • 9
    • 10
  1. 1.Department of Tumor BiologyOslo University HospitalOsloNorway
  2. 2.K.G. Jebsen Center for Breast Cancer ResearchUniversity of OsloOsloNorway
  3. 3.Institute of Clinical MedicineUniversity of OsloOsloNorway
  4. 4.The Intervention CentreOslo University HospitalOsloNorway
  5. 5.Department of Mathematical Sciences and TechnologyNorwegian University of Life SciencesÅsNorway
  6. 6.Department of Radiology and Nuclear MedicineOslo University HospitalOsloNorway
  7. 7.Department of OncologyOslo University HospitalOsloNorway
  8. 8.Department of PharmacyUniversity of TromsøTromsøNorway
  9. 9.Department of PhysicsUniversity of OsloOsloNorway
  10. 10.Department of Medical PhysicsOslo University HospitalOsloNorway

Personalised recommendations